We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+1.54%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$79.7M
AUM Growth
-$662M
(-89%)
Cap. Flow
-$660M
Cap. Flow
% of AUM
-828.28%
Top 10 Holdings %
Top 10 Hldgs %
21.47%
Holding
303
New
144
Increased
52
Reduced
48
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.36M |
| 2 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$1.1M |
| 3 |
ProShares Ultra Utilities
UPW
|
+$905K |
| 4 |
Lexicon Pharmaceuticals
LXRX
|
+$786K |
| 5 |
Puma Biotechnology
PBYI
|
+$617K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ETP
Energy Transfer Partners, L.P.
ETP
|
+$93.5M |
| 2 |
WPZ
Williams Partners L.P.
WPZ
|
+$65M |
| 3 |
BPL
Buckeye Partners, L.P.
BPL
|
+$48.9M |
| 4 |
Energy Transfer Partners
ET
|
+$45.2M |
| 5 |
Enterprise Products Partners
EPD
|
+$40.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.8% |
| 2 | Financials | 1.05% |
| 3 | Consumer Discretionary | 0.59% |
| 4 | Technology | 0.58% |
| 5 | Consumer Staples | 0.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
MacroGenics
MGNX
$235M
| $343K | 0.43% |
18,057
-392
| -2% | -$7.32K |
|
102
TG Therapeutics
TGTX
$8.58B
| $343K | 0.43% |
41,833
+12,380
| +42% | +$108K |
|
103
CytomX Therapeutics
CTMX
$705M
| $339K | 0.43% |
16,059
-8,018
| -33% | -$166K |
|
104
Celldex Therapeutics
CLDX
$2.77B
| $338K | 0.42% |
7,931
-1,387
| -15% | -$59.4K |
|
105
Alaunos Therapeutics
TCRT
$4.74M
| $338K | 0.42% |
545
+152
| +39% | +$109K |
|
|
TVRD
106
Tvardi Therapeutics
TVRD
$23.5M
| $338K | 0.42% |
768
+243
| +46% | +$111K |
|
107
Corbus Pharmaceuticals
CRBP
$170M
| $337K | 0.42% |
1,581
-283
| -15% | -$60.6K |
|
|
LUMO
108
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $336K | 0.42% |
+4,608
| New | +$381K |
|
|
ITCI
109
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $335K | 0.42% |
23,102
-7,498
| -25% | -$116K |
|
110
Inovio Pharmaceuticals
INO
$79.8M
| $334K | 0.42% |
6,738
+3,302
| +96% | +$205K |
|
|
ATNX
111
DELISTED
Athenex, Inc. Common Stock
ATNX
| $333K | 0.42% |
+1,047
| New | +$358K |
|
112
Novavax
NVAX
$1.23B
| $329K | 0.41% |
13,260
-2,154
| -14% | -$52.6K |
|
113
Iovance Biotherapeutics
IOVA
$2.23B
| $322K | 0.4% |
40,259
-14,264
| -26% | -$115K |
|
|
KDNY
114
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $321K | 0.4% |
8,547
+2,410
| +39% | +$105K |
|
|
AGEN
115
Agenus
AGEN
$249M
| $320K | 0.4% |
5,006
+190
| +4% | +$14.5K |
|
|
DOVA
116
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $318K | 0.4% |
+11,044
| New | +$303K |
|
117
Geron
GERN
$911M
| $314K | 0.39% |
174,683
+49,258
| +39% | +$99.5K |
|
|
AKCA
118
DELISTED
Akcea Therapeutics Inc
AKCA
| $314K | 0.39% |
+18,071
| New | +$354K |
|
|
MRNS
119
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $308K | 0.39% |
+9,451
| New | +$255K |
|
120
Itaú Unibanco
ITUB
$91.3B
| $139K | 0.17% |
+22,050
| New | +$141K |
|
121
Alibaba
BABA
$269B
| $132K | 0.17% |
+764
| New | +$137K |
|
122
America Movil
AMX
$78.1B
| $109K | 0.14% |
+6,344
| New | +$111K |
|
123
Ambev
ABEV
$47.3B
| $94K | 0.12% |
+14,591
| New | +$93.4K |
|
124
Fomento Económico Mexicano
FMX
$43.3B
| $80K | 0.1% |
+852
| New | +$77.7K |
|
125
Petrobras Class A
PBR.A
$107B
| $69K | 0.09% |
+6,997
| New | +$68.9K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q4 2017 Portfolio in Review
As of Q4 2017, Virtus ETF Advisers held 303 positions worth $79.7M, down 89% from $742M the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Virtus ETF Advisers withdrew a net $660M in Q4 2017, closing 59 positions and reducing 48 holdings. Its most notable exit was Energy Transfer Partners, L.P., an estimated $93.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 7.9% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Virtus ETF Advisers opened a new position in iShares MSCI India ETF worth $427K.
- Virtus ETF Advisers's largest Q4 2017 buy was iShares MSCI India ETF: 11,844 shares worth $427K.
- Virtus ETF Advisers added most to iShares 20+ Year Treasury Bond ETF in Q4 2017, an estimated $1.36M increase.
- Virtus ETF Advisers's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $1.55M.
- Virtus ETF Advisers fully exited Energy Transfer Partners, L.P. in Q4 2017, selling an estimated $93.5M.
- Virtus ETF Advisers's ten largest holdings make up 21% of its $79.7M portfolio in Q4 2017.
- Virtus ETF Advisers opened 144 new positions and closed 59 in Q4 2017.
- Virtus ETF Advisers's portfolio value fell 89% quarter-over-quarter to $79.7M.
Based on Virtus ETF Advisers's 13F filing for Q4 2017, filed 14 Feb 2018.